Teva In Transition: Generics, Specialty And ‘The Space Between’
In an interview, President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva’s late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.
You may also be interested in...
Chairman Philip Frost cited “slight differences” with Teva’s board as the reason that Jeremy Levin resigned. Analysts on a same day call grilled the chairman on Teva’s practice to deny corporate executives a seat on its board, and on the resulting misalignment of board and management objectives.
More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?